Astrazeneca Down 3% Despite Citigroup Upgrade

On Tuesday, Citigroup upgraded shares of Astrazeneca AZN from Neutral to Buy and raised the price target from $20.80 to $29.12. Analyst Andrew Baum believes the reported £60 billion bid from Pfizer PFE “looks highly probable.” Although the Astrazeneca CEO, Ian Read, will likely try to retains the company's independence, Baum sees “limited defense strategies.” Baum feels a Pfizer acquisition, “would fit the company's strategic goals for immunotherapy and autoimmune disease.” Shares of Astrazeneca are down 3.3 percent to $66.81 in Tuesday's trading.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesAnalyst RatingsAndrew BaumCitigroup
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!